Novabay Pharmaceutic (NBY) Releases Quarterly Earnings Results
Novabay Pharmaceutic (NYSE: NBY) announced its earnings results on Thursday. The company reported ($0.08) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.09) by $0.01.
On a related note, analysts at Ascendiant Capital Markets initiated coverage on shares of Novabay Pharmaceutic in a research note to investors on Wednesday, March 6th. They set a “strong-buy” rating and a $2.25 price target on the stock.
Novabay Pharmaceutic (NBY) opened at 1.25 on Thursday. Novabay Pharmaceutic (NBY) has a 52-week low of $0.88 and a 52-week high of $1.76. The stock’s 50-day moving average is currently $1.23. The company’s market cap is $37.3 million.
NovaBay Pharmaceuticals, Inc. (NovaBay) is a clinical-stage pharmaceutical company, which is engaged in the discovery and development of synthetic anti-infective product candidates to treat and prevent a range of infections, without developing resistance, in hospital and non-hospital environments.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.